Compare ADT Inc (ADT) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? ADT Inc trades at $7.37 (market cap $5.44B), while Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.4× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ADT | ALNY | |
|---|---|---|
Market Cap | $5.44B | $29.60B |
Sector | Industrials | Health |
52-Week High | $8.85 | $491.22 |
52-Week Low | $6.30 | $205.48 |
Enterprise Value | $13.13B | $27.56B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.
Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
